OKUR · OnKure Therapeutics, Inc. · Executive Compensation
$3.10
-0.17 (-5.20%)
At close · Sep 11
Going-concern doubt
— cleared Aug 4, 2026
The latest filing states the doubt was alleviated.
“As of December 31, 2025, the Company had determined that substantial doubt about the Company's ability to continue as a going concern for a period of at least 12 months from the date of the issuance of those financial statements did exist. However, following completion of the 2026 Private Placement (see Note 9), management believes the Company's cash, cash equivalents and marketable securities will be sufficient to fund its current operating plan for at least the next 12 months from the date of issuance of these condensed consolidated financial statements and as such substantial doubt has been alleviated.”View the 10-Q filed Aug 4, 2026
Market Cap
$125.54M
Shares
40.50M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Nicholas A. Saccomano | President and Chief Executive Officer | $1,467,934 |
| Jason Leverone | C.P.A. Chief Financial Officer | $896,167 |
| Samuel Agresta | Chief Medical Officer | $851,731 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Nicholas A. Saccomano | President and Chief Executive Officer | $9,515,165 |
| Samuel Agresta | Chief Medical Officer | $2,841,068 |
| Jason Leverone | C.P.A. Chief Financial Officer | $2,678,570 |
| Gregory J. Flesher | Former President and Chief Executive Officer | $1,779,607 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Jason Leverone | C.P.A. Chief Financial Officer | $791,947 |
| Gregory J. Flesher | Former President and Chief Executive Officer | $569,704 |
| Nicholas A. Saccomano | President and Chief Executive Officer | $308,852 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Gregory J. Flesher | President and Chief Executive Officer | $1,193,452 |
| Ashley F. Hall | Chief Development Officer | $825,304 |
| Michael P. Cruse | Chief Operating Officer | $781,474 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Gregory J. Flesher | President and Chief Executive Officer | $5,369,470 |
| Michael P. Cruse | Chief Operating Officer | $1,496,036 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Gregory J. Flesher | Chief Executive Officer and President Vineet R. Jindal\ | $132,947 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Edward T. Mathers | Class II director | Appointed | 2026-06-04 |
| Valerie M. Jansen | Class II director | Appointed | 2026-06-04 |
| R. Michael Carruthers | Class II director | Appointed | 2026-06-04 |
| Dr. Liam Ratcliffe | Class I director | Appointed | 2026-03-30 |
| Valerie M. Jansen | member of the Board of Directors of OnKure | Appointed | 2024-10-08 |
| Nicholas A. Saccomano | President and Chief Executive Officer of OnKure | Appointed | 2024-10-08 |
| Andrew Phillips | Chair of the Board | Appointed | 2024-10-08 |
| Edward T. Mathers | Class II director | Appointed | 2024-10-08 |
| Andrew Phillips | Class III director | Appointed | 2024-10-08 |
| Michael Grey | Class III director | Appointed | 2024-10-08 |
| Valerie M. Jansen | Class II director | Appointed | 2024-10-08 |
| R. Michael Carruthers | Class II director | Appointed | 2024-10-08 |
| Isaac Manke | Class I director | Appointed | 2024-10-08 |
| Nicholas Saccomano | Class I director | Appointed | 2024-10-08 |
| Dylan Hartley | Chief Scientific Officer | Appointed | 2024-10-08 |
| Samuel Agresta | Chief Medical Officer | Appointed | 2024-10-08 |
| Jason Leverone | Chief Financial Officer (Principal Financial and Accounting Officer) | Appointed | 2024-10-08 |
| Nicholas Saccomano | President and Chief Executive Officer (Principal Executive Officer) | Appointed | 2024-10-08 |
| Ashley F. Hall, J.D. | Chief Development Officer | Terminated | 2024-09-13 |
Key facts
CIK
1637715
CUSIP
68277Q105
13F (30d)
40 filings
40 filers
Visit website
Investor relations